Exagen Inc
XGN
Company Profile
Business description
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
Contact
1261 Liberty Way
VistaCA92081
USAT: +1 760 560-1501
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
209
Stocks News & Analysis
stocks
Nvidia: Collaboration with Intel might bring some goodwill with the US
We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.
stocks
What now for Santos after takeover offer collapses?
Our Fair Value estimate once again reflects the stand-alone business and its growth potential.
stocks
Morningstar initiates coverage on small cap ASX REIT
Coverage of ASX listed REIT as investor interest in property continues to grow.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,061.20 | 20.50 | -0.23% |
| CAC 40 | 7,887.21 | 32.60 | 0.42% |
| DAX 40 | 23,677.28 | 2.75 | 0.01% |
| Dow JONES (US) | 46,241.40 | 98.98 | 0.21% |
| FTSE 100 | 9,233.75 | 5.64 | 0.06% |
| HKSE | 26,545.10 | 0.25 | 0.00% |
| NASDAQ | 22,569.62 | 98.90 | 0.44% |
| Nikkei 225 | 45,045.81 | 257.62 | -0.57% |
| NZX 50 Index | 13,231.66 | 111.63 | 0.85% |
| S&P 500 | 6,647.30 | 15.34 | 0.23% |
| S&P/ASX 200 | 8,773.50 | 18.70 | -0.21% |
| SSE Composite Index | 3,820.09 | 11.57 | -0.30% |